These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22610787)

  • 1. Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.
    Masui Y; Asano Y; Takahashi T; Shibata S; Akamata K; Aozasa N; Noda S; Taniguchi T; Ichimura Y; Toyama T; Tamaki Z; Sumida H; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
    Mod Rheumatol; 2013 Mar; 23(2):323-9. PubMed ID: 22610787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.
    Takahashi T; Asano Y; Akamata K; Aozasa N; Taniguchi T; Noda S; Masui Y; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2013 Sep; 23(5):884-90. PubMed ID: 22972016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
    Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
    J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
    Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
    Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
    Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
    J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up.
    Tochimoto A; Kawaguchi Y; Hara M; Tateishi M; Fukasawa C; Takagi K; Nishimagi E; Ota Y; Katsumata Y; Gono T; Tanaka E; Yamanaka H
    Mod Rheumatol; 2011 Jun; 21(3):296-301. PubMed ID: 21240620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases.
    Takahashi T; Asano Y; Amiya E; Hatano M; Tamaki Z; Ozeki A; Watanabe A; Kawarasaki S; Nakao T; Taniguchi T; Ichimura Y; Toyama T; Watanabe M; Hirata Y; Nagai R; Sato S
    Mod Rheumatol; 2012 Aug; 22(4):598-601. PubMed ID: 22015621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
    Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
    J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
    Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
    Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide.
    Abhishek A; Yazdani R; Pearce F; Regan M; Lim K; Hubbard R; Lanyon P
    Clin Rheumatol; 2011 Aug; 30(8):1099-104. PubMed ID: 21484227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options for systemic sclerosis related interstitial lung diseases.
    Mouthon L; Bérezné A; Guillevin L; Valeyre D
    Respir Med; 2010 Jul; 104 Suppl 1():S59-69. PubMed ID: 20630349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
    Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
    Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis.
    Takahashi T; Asano Y; Yamashita T; Nakamura K; Saigusa R; Miura S; Ichimura Y; Toyama T; Hirabayashi M; Taniguchi T; Yoshizaki A; Sato S
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):291-297. PubMed ID: 28681537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
    Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
    Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.